According to FutureWise analysis, the type streptococcus rapid test market in 2025 is US$220.3 million, and is expected to reach over US$416.05 million by 2033 at a CAGR of 8.27%. The rising prevalence of streptococcal infections and the increasing demand for point-of-care diagnostics are major factors driving market growth. Additionally, advancements in rapid antigen detection technologies and their broader use in hospitals, clinics, and diagnostic laboratories are contributing to this expansion. Greater awareness of the importance of early diagnosis and treatment efficiency is also fueling the global demand for rapid testing of streptococcal infections. In 2023, the market for rapid tests for Group A Streptococcus was valued at $34 million and is expected to exceed $60 million by 2031, growing at a compound annual growth rate (CAGR) of 8.6%. This growth is primarily driven by the rising incidence of streptococcal infections, particularly among children and the elderly, as well as the demand for quick and accurate point-of-care diagnostics. Improved test sensitivity and heightened awareness of the benefits of early detection are also contributing to the adoption of these tests.

Group A streptococcus, also known as streptococcus pharyngitis, is a type of bacteria that can cause various infections, including strep throat, scarlet fever, and more serious invasive diseases. Strep throat is an infection that affects the throat and tonsils, primarily spread from person to person through coughing or sneezing. Although anyone can get strep throat, it is most common in children aged 5 to 15. Strep throat is easily treated with antibiotics; however, if left untreated, it can lead to severe complications. These complications include rheumatic fever, which affects the heart and joints, and glomerulonephritis, a type of kidney disease.

From 2024 to 2025, the Type A Streptococcus Rapid Test Market saw significant advancements. Roche received FDA clearance for its cobas Strep A test, while Abbott launched the ID NOW Strep A 2, which provides results in six minutes without requiring culture confirmation. QuidelOrtho expanded its Sofia Strep A FIA platform, and VivaChek gained IVDR certification in Europe for self-testing kits, indicating a shift toward at-home diagnostics. Innovative methods, such as saliva-based sampling and expanded distribution through pharmacies, are enhancing convenience and access, reflecting a strong trend toward rapid molecular diagnostics and regulatory acceptance of self-testing.

FutureWise Market Research has instantiated a report that provides an intricate analysis of A Type Streptococcus Rapid Test Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=3783&type=requestsample

By Product Type

• Colorimetric Method
• Immune Chromatography

By Application

• Hospitals
• Family
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Here’s a regional view of where the most progress is happening:

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. North America has been experiencing a favourable rise for the A type streptococcus rapid test market during the anticipated period due to recent technological advancements and the existence of a number of unique medication molecules to improve the treatment technique. North America has a well-established healthcare infrastructure with advanced diagnostic facilities and a high level of awareness about the importance of early diagnosis and treatment of infectious diseases, including streptococcal infections. This has led to increased adoption of rapid diagnostic tests for streptococcal infections in the region.

Competitive Landscape in A-type Streptococcus Rapid Test Market:

• AccuBioTech
• Alere
• Concile GmbH
• CorisBioConcept
• EKF Diagnostics
• ELITech Group
• LifeSign PBM
• Hologic
• Quidel

Recent developments by key players in the A Type Streptococcus Rapid Test Market:

Quidel Corporation

• In 2023, a next-generation rapid diagnostic kit was launched, featuring enhanced sensitivity for detecting the Group A Strep antigen. This innovation aims to enhance diagnostic accuracy in point-of-care settings.

EKF Diagnostics

• The QuStick™ Strep A rapid test kit is a dip-stick immunoassay that detects Group A Streptococcus antigen from throat swabs in just 5 minutes. With an enhanced sensitivity of ~97%, it remains effective at low bacterial counts and is CLIA-waived, allowing for room-temperature storage and a 20-month shelf life.

AccuBioTech

• A Rapid Test Cassette is a chromatographic immunoassay designed for the qualitative detection of Group A Streptococcus antigen from throat swabs. Although this product is marketed globally, specific recent enhancements or regional approvals have not been publicly disclosed as of early 2025.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=3783&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the A Type Streptococcus Rapid Test Market By Product Type, By Application and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com